Finoriq research workspace
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Company Overview
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for. Review AAPG filings, fundamentals, valuation, and ownership on Finoriq.
Company Snapshot
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
- Company
- ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
- Ticker
- AAPG
- Market Cap
- $1.7B
- Latest Price
- $18.37
- Industry
- Biotech & Pharma
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Current Valuation Metrics
Static valuation preview for ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG). Market data retrieved 2026-07-08. Filing currency CNY.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 12.0x | Revenue | TTM FY 2024 |
| Earnings YieldLatest TTM net income divided by market cap. | -3.4% | Net Income | TTM FY 2024 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -0.95% | Operating Cash Flow | TTM FY 2024 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.